Showing results (1081-1090 of 1,322) with videos related to

Sort By:
Pageof 133
Diabetes Care|September 15, 2021
Natriuretic Peptides and Risk of Type 2 Diabetes: Results From the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) ConsortiumChaterina Sujana, Veikko Salomaa, Frank Kee, et al.
Virchows Archiv : an International Journal of Pathology|September 13, 2006
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemG Rindi, G Klöppel, H Alhman, et al.
The Journal of Pathology|June 22, 2000
Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?E van der Harst, H A Bruining, H Jaap Bonjer, et al.
Thorax|January 26, 2002
Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitalsG J M Herder, P Verboom, E F Smit, et al.
Journal of Clinical Pathology|March 31, 2012
Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancerA Jasmijn Hubers, Daniëlle A M Heideman, Gerarda J M Herder, et al.
Diabetes/Metabolism Research and Reviews|August 17, 2018
Association of changes in inflammation with variation in glycaemia, insulin resistance and secretion based on the KORA studyTonia de Las Heras Gala, Christian Herder, Femke Rutters, et al.
The Journal of Clinical Endocrinology and Metabolism|January 10, 2003
Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitroRichard A Feelders, Steven W J Lamberts, Leo J Hofland, et al.
Diabetes|July 5, 2008
Distinct monocyte gene-expression profiles in autoimmune diabetesRoos C Padmos, Nanette C Schloot, Huriya Beyan, et al.
Anticancer Research|February 7, 2016
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine TumoursNicola Fazio, Roberto Buzzoni, Eric Baudin, et al.
The Oncologist|December 10, 2020
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?Elettra Merola, Teresa Alonso Gordoa, Panpan Zhang, et al.
Pageof 133